Mitapivat versus Placebo for Pyruvate Kinase Deficiency
Al-Samkari, Hanny; Galactéros, Frédéric; Glenthøj, Andreas; Rothman, Jennifer A.; Andres, Oliver; Grace, Rachael F.; Morado-Arias, Marta; Layton, D. Mark; Onodera, Koichi; Verhovsek, Madeleine; Barcellini, Wilma; Chonat, Satheesh; Judge, Malia P.; Zagadailov, Erin; Xu, Rengyi; Hawkins, Peter; Beynon, Vanessa; Gheuens, Sarah; van Beers, Eduard J.; the ACTIVATE Investigators
(2022) New England Journal of Medicine, volume 386, issue 15, pp. 1432 - 1442
(Article)
Abstract
BACKGROUND Pyruvate kinase deficiency is a rare, hereditary, chronic condition that is associated with hemolytic anemia. In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency. METHODS In this global, phase 3, randomized, placebo-controlled trial, we
... read more
evaluated the efficacy and safety of mitapivat in adults with pyruvate kinase deficiency who were not receiving regular red-cell transfusions. The patients were assigned to receive either mitapivat (5 mg twice daily, with potential escalation to 20 or 50 mg twice daily) or placebo for 24 weeks. The primary end point was a hemoglobin response (an increase from baseline of ≥1.5 g per deciliter in the hemoglobin level) that was sustained at two or more scheduled assessments at weeks 16, 20, and 24. Secondary efficacy end points were the average change from baseline in the hemoglobin level, markers of hemolysis and hematopoiesis, and the change from baseline at week 24 in two pyruvate kinase deficiency-specific patient-reported outcome measures. RESULTS Sixteen of the 40 patients (40%) in the mitapivat group had a hemoglobin response, as compared with none of the 40 patients in the placebo group (adjusted difference, 39.3 percentage points; 95% confidence interval, 24.1 to 54.6; two-sided P<0.001). Patients who received mitapivat had a greater response than those who received placebo with respect to each secondary end point, including the average change from baseline in the hemoglobin level. The most common adverse events were nausea (in 7 patients [18%] in the mitapivat group and 9 patients [23%] in the placebo group) and headache (in 6 patients [15%] and 13 patients [33%], respectively). Adverse events of grade 3 or higher occurred in 10 patients (25%) who received mitapivat and 5 patients (13%) who received placebo. CONCLUSIONS In patients with pyruvate kinase deficiency, mitapivat significantly increased the hemoglobin level, decreased hemolysis, and improved patient-reported outcomes. No new safety signals were identified in the patients who received mitapivat.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Adult, Anemia, Hemolytic, Congenital Nonspherocytic/drug therapy, Double-Blind Method, Hemoglobins/analysis, Hemolysis/drug effects, Humans, Piperazines/pharmacology, Pyruvate Kinase/deficiency, Pyruvate Metabolism, Inborn Errors/drug therapy, Quinolines/pharmacology, General Medicine, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article
ISSN: 0028-4793
Publisher: Massachussetts Medical Society
Note: Funding Information: Supported by Agios Pharmaceuticals . Publisher Copyright: Copyright © 2022 Massachusetts Medical Society Copyright © 2022 Massachusetts Medical Society.
(Peer reviewed)